Amit Johnsingh, MD
Nephrology · Temple Terrace, FLNPI 1861470916
Payments from drug & device makers
Across 146 payments — averaging $10,248 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$741K
- AstraZeneca$286K
- Astrazeneca UK Limited$265K
- Novartis$116K
- Eli Lilly$54K
- Aurinia Pharma U.S., Inc.$32K
- plus $3K from 19 others
Across 2 payments — averaging $26,183 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$52K
What the payments were for
- Food & beverage$2,90797%
- Education$863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 14 | $740,663 |
| AstraZeneca(2 entities) | 10 | $285,906 |
| Astrazeneca UK Limited | 4 | $264,903 |
| Novartis | 12 | $116,084 |
| Eli Lilly | 1 | $54,315 |
| Aurinia Pharma U.S., Inc. | 22 | $31,857 |
| Boehringer Ingelheim International GmbH | 7 | $411 |
| Amgen(2 entities) | 15 | $387 |
| Otsuka America Pharmaceutical, Inc. | 11 | $323 |
| Akebia Therapeutics Inc | 10 | $243 |
| Travere Therapeutics, Inc. | 3 | $196 |
| Mallinckrodt Hospital Products Inc. | 5 | $139 |
| Bayer | 6 | $127 |
| Vantive US Healthcare LLC | 1 | $116 |
| Baxter Healthcare | 2 | $104 |
| Novo Nordisk | 4 | $94 |
| Fresenius USA Marketing, Inc. | 4 | $89 |
| Calliditas Therapeutics US Inc. | 3 | $74 |
| Ardelyx, Inc. | 3 | $62 |
| OPKO Pharmaceuticals, LLC | 3 | $53 |
| Lilly USA, LLC | 2 | $39 |
| Daiichi Sankyo Inc. | 1 | $24 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $19 |
| GSK | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- KRYSTEXXA$125
- LUPKYNIS$124
- Renal - Acute$116
How this compares
$1,496,269 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 92 | $115,629 |
| FarxigaDapagliflozin Propanediol | 106 | $102,505 |
| EliquisApixaban | 18 | $23,320 |
| OzempicSemaglutide | 21 | $20,570 |
| KerendiaFinerenone | 11 | $6,860 |
| Candesartan Cilexetil | 40 | $3,454 |
| Nifedipine ErNifedipine | 76 | $3,167 |
| Valsartan | 115 | $3,136 |
| Calcitriol | 83 | $2,671 |
| Bumetanide | 37 | $2,425 |
| Sevelamer Carbonate | 12 | $1,161 |
| Furosemide | 111 | $1,089 |
| Carvedilol | 166 | $1,072 |
| Losartan Potassium | 65 | $965 |
| Hydralazine Hcl | 43 | $808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $740,663 | $115,62992 claims |
| AstraZenecaFarxiga | $285,906 | $102,505106 claims |
| Novo NordiskOzempic | $94 | $20,57021 claims |
| BayerKerendia | $127 | $6,86011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.
Other nephrology in Temple Terrace
- Pablo Ruiz-RamonTemple Terrace$1.2M
- Jason RothschildTemple Terrace$413K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.